NeuroPace Reports 24% Q4 Revenue Growth, Positive Adjusted EBITDA, and Key FDA Submissions
Summary
NeuroPace reported strong fourth-quarter 2025 financial results, with total revenue growing 24% year-over-year to $26.6 million and achieving its second consecutive quarter of positive Adjusted EBITDA at $0.9 million. Full-year 2025 revenue reached $100.0 million, a 25% increase from 2024. The company also provided a 2026 outlook, projecting total revenue between $98 million and $100 million, representing 20% to 22% RNS revenue growth, though Adjusted EBITDA is expected to be negative. Strategically, NeuroPace submitted a PMA-S to the FDA for an expanded indication of its RNS System for idiopathic generalized epilepsy and also submitted Seizure ID™, an AI tool, to the FDA. Favorable Medicare reimbursement updates for RNS System procedures starting in 2026 further bolster the outlook. These positive financial and operational developments are significant for the company, indicating strong commercial momentum and potential for future growth through product expansion and improved reimbursement. Investors will be watching the progress of the FDA submissions and the company's path to sustained profitability.
At the time of this announcement, NPCE was trading at $15.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $460.6M. The 52-week trading range was $7.56 to $18.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.